Recently a drug is been developed which is highly immunogenic vaccine delivery system for emerging infectious disease indications where the rapid induction of neutralizing antibodies is needed to protect against the viruses that cause hemorrhagic fevers such as Ebola, Marburg, and Lassa. This technology of vaccine delivery is based on seminal discoveries made in the laboratory and patented by Yale University. Building on these discoveries, scientists introduced multiple non-reversible genetic modifications into the prototype that synergistically attenuate the virus and provide vectors that are safe for human use. To extend the platform, studies are conducted with scientists and collabrations at the University of Texas Medical Branch that have identified additional vesiculoviruses with utility as vaccine vectors. The resulting platform consists of a family of non-cross reactive vaccine vectors that are constructed and attenuated so they do not cause illness in animal or humans using methods exemplified with rVSV. It is been demonstrated the safety and immunogenicity of its vaccines against HIV in human clinical trials.